Natera, Inc. (NASDAQ:NTRA) Insider Sells $30,737.92 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 256 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Natera Price Performance

NTRA stock opened at $117.67 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $133.54. The firm has a market cap of $14.55 billion, a P/E ratio of -48.03 and a beta of 1.53. The company’s 50-day moving average price is $123.24 and its two-hundred day moving average price is $111.24.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the firm earned ($0.97) EPS. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. On average, analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares in the last quarter. Farallon Capital Management LLC boosted its stake in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after purchasing an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Natera by 6.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after purchasing an additional 148,917 shares in the last quarter. Duquesne Family Office LLC boosted its stake in shares of Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after purchasing an additional 45,500 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock valued at $156,092,000 after purchasing an additional 246,246 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on NTRA shares. Leerink Partners increased their price objective on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Stephens reissued an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. Canaccord Genuity Group increased their price objective on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Friday. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.